论文部分内容阅读
目的:目的:探讨miR-194-2-192簇与鼠双微体基因2(MDM2)在多发性骨髓瘤(MM)中的表达及临床意义。方法:留取MM患者骨髓标本21例,应用嵌合荧光法(SYBR?GreenⅠ)的实时荧光定量PCR(qRT-PCR)法检测miR-194-2-192簇和MDM2的表达情况,并用2-△△Ct方法进行相对定量分析。以10例健康体检者作为对照。结果:miR-194-2-192簇在MM患者中的表达显著低于对照者,而MDM2的表达显著高于对照组(均P<0.05),且均与ISS临床分期有关(均P<0.05)。miRNA-192与MDM2呈显著负相关(r=-0.353,P=0.035)。经过不同治疗后,MM患者中硼替佐米治疗者的MDM2表达水平显著低于VAD(长春新碱+阿霉素+地塞米松)治疗者(P<0.05)。结论:MDM2是miR-192的直接靶基因。miRNA-194-2-192簇低表达和MDM2高表达可能是MM发病发展的重要因子。
Objective: To investigate the expression of miR-194-2-192 cluster and murine double-gene 2 (MDM2) in multiple myeloma (MM) and its clinical significance. METHODS: Twenty-one bone marrow samples from patients with MM were collected and the expression of miR-194-2-192 cluster and MDM2 were detected by real-time quantitative PCR (qRT-PCR) with chimeric fluorescence (SYBR Green Ⅰ) △△ Ct method for relative quantitative analysis. 10 healthy people as a control. Results: The expression of miR-194-2-192 cluster in MM patients was significantly lower than that in controls, while the expression of MDM2 was significantly higher than that in control group (all P <0.05) ). There was a significant negative correlation between miRNA-192 and MDM2 (r = -0.353, P = 0.035). After different treatments, MDM2 expression was significantly lower in patients treated with bortezomib than those treated with VAD (vincristine + doxorubicin + dexamethasone) (P <0.05). Conclusion: MDM2 is a direct target of miR-192. Low expression of miRNA-194-2-192 cluster and high expression of MDM2 may be an important factor in the pathogenesis of MM.